The ASCO Gastrointestinal Cancers Symposium 2026 (ASCO GI 2026), a premier global oncology event, is currently taking place from January 8-10, 2026, at the Moscone Center West in San Francisco, California, and online. This annual symposium brings together oncologists, researchers, and healthcare professionals worldwide to discuss the latest advancements in GI cancer treatment, research, and patient care. Oncodaily, an oncology news platform, is actively providing coverage and aggregating key highlights from the conference, including a compilation of '15 Posts Not To Miss From ASCO GI 2026, part 1'. These posts offer timely insights into the proceedings. Among the notable discussions are sessions on managing the increasing incidence of early-onset GI cancers, harnessing artificial intelligence for GI oncology, and innovative approaches to various GI malignancies. Prominent figures are sharing their perspectives and findings. Udhayvir Grewal, a GI Oncologist, shared his focus on neuroendocrine tumors (NETs) during the symposium. Amol Akhade, a Senior Consultant at Fortis Hospitals Mumbai, has provided updates on late-breaking abstracts and major multidisciplinary team (MDT) sessions, particularly highlighting trials in colorectal and gastric cancers. Akhade is also organizing a global webinar on January 12, 2026, to help professionals make sense of the data presented at ASCO GI 2026, demonstrating the event's global reach and continued relevance for an Indian audience. Additionally, Rachna Shroff, an ASCO expert in GI cancers, emphasized the "practice-changing" results of the HERIZON-GEA-01 trial, which investigates zanidatamab with chemotherapy for HER2-positive gastroesophageal adenocarcinoma. Her comments underscore the significant impact of the research presented. The articles from Oncodaily accurately reflect the ongoing nature and importance of the ASCO GI 2026 Symposium, serving as a credible source for updates from this critical oncology conference.